Business Context and Reporting Period
This Form 8-K Current Report was filed by Allarity Therapeutics, Inc. on March 28, 2022. The filing details a strategic restructuring of the company's rights regarding its cancer treatment drug, LiPlaCis®. The Company, an emerging growth company, entered into an Amended and Restated License Agreement and a Support Agreement with LiPlasome Pharma ApS, Chosa ApS, and Smerud Medical Research International AS.
Key Financial Metrics and Agreements
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt) as it is a current report on specific events. However, it outlines the following financial terms:
- Upfront Payment Obligation: Allarity agreed to pay LiPlasome 2,273,020 Danish Kroner upon execution of the Support Agreement to satisfy prior debt cancellation obligations.
- Future Milestone Payments: Allarity is entitled to receive up to $3.5 million in milestone payments from Chosa, shared with LiPlasome, contingent upon regulatory approvals in the U.S. and Europe and the achievement of cumulative net sales thresholds.
- Licensing Terms: Allarity granted Chosa an exclusive, royalty-free, transferable, and sublicensable license for DRP® Companion Diagnostics specific to Cisplatin or LiPlaCis®.
Material Changes Versus Prior Period
The filing reports a significant change in the Company's asset portfolio and commercial rights:
- Transfer of Rights: Chosa replaced Allarity Europe as the exclusive licensee for the development and commercialization of LiPlaCis®. Consequently, Allarity no longer holds rights to use or commercialize LiPlaCis®.
- Termination of Sublicense: The 2020 Sublicense Agreement with Smerud regarding LiPlaCis® was terminated. However, discussions regarding the further development of 2X-111 (a Phase 2-stage cancer drug) with Smerud are ongoing.
- Revenue Model Shift: The Company's potential revenue from LiPlaCis® has shifted from active commercialization to a passive model dependent solely on the achievement of specific regulatory and sales milestones by Chosa.
- Milestone Dependency: The realization of the up to $3.5 million in potential payments is contingent on future events (regulatory approvals and sales) that are not guaranteed.
- Loss of Control: Allarity has relinquished control over the development and commercialization strategy of LiPlaCis® to Chosa.
- Contractual Obligations: The Company incurred an immediate cash outflow obligation (2,273,020 DKK) to settle prior obligations with LiPlasome.
- Verify the exact USD equivalent of the 2,273,020 Danish Kroner payment obligation at the time of execution.
- Confirm the specific regulatory and sales thresholds required to trigger the $3.5 million in milestone payments.
- Review the status of ongoing discussions with Smerud regarding the 2X-111 drug to assess future pipeline potential.
- Examine the redacted exhibits (Amended License Agreement and Support Agreement) in the upcoming Form 10-K for detailed legal terms and confidentiality restrictions.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The Company has exited the direct commercialization of LiPlaCis® but retains a financial interest through milestone payments. The Company is continuing discussions with Smerud regarding 2X-111, indicating a continued focus on this specific asset.
Risks and Contingencies: